[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bai-Rong Xia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100602582","phase-2-chemotherapy-combined-with-propranolol-hydrochloride-as-neoadjuvant-therapy-for-advanced-high-grade-serous-ovarian-cancer-100602582",false,"NCT07125391","Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer: A Prospective, Multicenter, Phase II Clinical Study","Inclusion Criteria:\n\n* Written informed consent was obtained before any trial-related procedures were performed.\n* Women, 18 to 75 years old;\n* FIGO stage for stage III or IV, including not surgery in patients with stage III or IV beginning for ovarian cancer; Histopathology confirmed high-grade serous ovarian cancer.\n* According to the response evaluation criteria in 1.1 (RECIST1.1) definition, patients must have a measurable lesions\n* Agreed to provide the participants formalin fixed and tumor tissue specimens or fresh biopsy tissue tumor lesions markers detection\n* ECOG score 0-1 points\n* Expected survival time 6 months or more\n* Enough organ function, without severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction, and immune deficiency, participants need to satisfy the following laboratory indicators\n\n  * hemoglobin (HGB) 90 g\u002FL or higher\n  * Neutrophils (NEUT) acuity 1.5 x 109 \u002F L or white blood cell count (WBC) or 3 x 109 \u002F L\n  * Platelet (PLT) or 90 x 109 \u002F L\n  * Nmda aminotransferase (AST) 2.5 x ULN or less\n  * Alanine aminotransferase (ALT) 2.5 x ULN or less\n  * Total bilirubin (TBIL) 1.5 x ULN or less\n  * Serum creatinine (SCr) 1.0 x ULN or less\n  * Potential fertility women in the group of 7 days before the serum or urine HCG were negative (postmenopausal women considered must be at least 12 months of amenorrhea fertility; Pregnancy tests are not required for women with documented tubal ligation)\n  * Potential fertility women are willing to take in the experiment of the medical contraception\n\nExclusion Criteria:\n\n* Malignant diseases other than ovarian cancer (excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, and\u002For radical resection in situ carcinoma) diagnosed within 5 years before the first dose\n* Current are participating in clinical research and treatment of intrusive, or within 4 weeks before the first dose received study used drugs or other treatments\n* Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy\n* Need treatment of symptomatic or non-control brain metastasis at the same time, including but not limited to, surgery, radiation and\u002For corticosteroids, or with the clinical manifestations of spinal cord compression\n* Current use of oral or intravenous beta blockers (atenolol, peso parlour, carvedilol and labetalol, metoprolol, than the parlour, his law such as beta blockers) cannot safely use of propranolol\n* Patients who have previously used propranolol, particularly those who were still on continuous use or had discontinued the medication for less than 14 days within 14 days prior to enrollment, are ineligible for inclusion. Those who have discontinued the medication for ≥14 days and meet the safety criteria as determined by the investigator may be selected for enrollment.\n* Patients with contraindications to β-blockers were excluded according to the contraindications in the propranolol package insert.\n* Patients were receiving systemic glucocorticoids (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days before the first study dose; Note: allows the use of physiological doses of corticosteroids (10 mg\u002Fday or less prednisone or equivalent drugs)\n* Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation\n* Patients who were allergic to the active ingredient or excipients of propranolol hydrochloride in this study\n* Have not fully recovered from any intervention-related toxicity and\u002For complications before starting treatment (i.e., ≤ grade 1 or baseline, excluding fatigue or alopecia)\n* Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive)\n* Hepatitis b patients with known\n* Activity of HCV infection subjects (HCV antibody positive and HCV - RNA levels higher than the detection limit)\n* For the first time to give medicine before (1 cycle, day 1) vaccinated live vaccine within 30 days\n* Pregnant or lactating women\n* Any serious or uncontrolled systemic disease, such as\n\n  * resting electrocardiogram (ecg) in rhythm, conduction, or have a significant and severe symptoms to appear on the form is hard to control the exceptions, such as complete left bundle branch block, Ⅱ degrees above heart block, ventricular arrhythmia or atrial fibrillation\n  * Unstable angina and congestive heart failure, New York heart association (NYHA) classification of grade 2 or more chronic heart failure\n  * Within 6 months before the selected treatment had any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, etc.\n  * First dose exist within 1 year before need to glucocorticoid treatment of infectious pneumonia history, or the current clinical activity interstitial lung disease; Active tuberculosis\n  * There need systemic treatment of active or failure to control the infection\n  * Clinical activity diverticulitis, abdominal abscess, gastrointestinal obstruction\n  * Liver disease such as cirrhosis of the liver, decompensated liver disease, acute or chronic active hepatitis\n  * Mental disorders and unable to cooperate with treatment\n* Any medical history or evidence of illness, abnormal treatment or laboratory values, or other conditions that might interfere with the results of the trial or prevent full participation in the study, or any other potential risk that might be considered by the investigator to be inappropriate for enrollment.","FEMALE","18 Years","75 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enhance resistance to PD - 1 the activity of the inhibitor, to improve the treatment of mice on the immune response. Non-selective β-blockers can also improve the efficacy of melanoma immunotherapy. Retrospective studies have shown that incidental use of β-blockers in combination with antiangiogenic agents, chemotherapy, and immune therapy can prolong DFS, PFS, and OS in cancer patients. A large, multicenter retrospective study found that ovarian cancer patients who took nonselective β-blockers for hypertension had better survival than those who did not. In conclusion, this study aims to explore new auxiliary chemotherapy combined propranolol treatment of high efficacy and safety of ovarian cancer, provide more evidence-based basis for clinic.",[27],"Ovarian Cancer",[29],"NACT","RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":34},"2025-06-20",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Bai-Rong Xia","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":42},"100643907","phase-2-an-exploratory-study-on-the-use-of-ipalotinib-tislelizumab-combined-with-sunitinib-and-olaparib-for-neoadjuvant-therapy-in-hrd-positive-advanced-ovarian-cancer-100643907","NCT07667751","An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged ≥18 years and ≤75 years at enrollment;\n2. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, with histopathological confirmation of high-grade serous carcinoma or endometrioid carcinoma, and FIGO stage (2014 edition) III-IV;\n3. Meeting the neoadjuvant indications for ovarian cancer (preoperative evaluation by a gynecologic oncologist indicates low likelihood of achieving R0 resection with initial debulking surgery, or the patient's physical condition is unsuitable for immediate surgery due to poor tolerance to PDS);\n4. Positive HRD testing result;\n5. Presence of at least one measurable lesion meeting RECIST 1.1 criteria;\n6. Expected survival time ≥12 weeks;\n7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n8. Absence of severe hematologic, cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency disorders. Within one week prior to the first administration, the functional status of vital organs must meet the following requirements (supportive therapies such as any blood components or cell growth factors are prohibited within 14 days before the first dose):\n\n   1. Complete blood count: HGB ≥ 90 g\u002FL; WBC ≥ 4.0 × 10⁹\u002FL; NEUT ≥ 2.0 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL;\n   2. Blood biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN with creatinine clearance ≥ 50 mL\u002Fmin;\n   3. Coagulation function: INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;\n   4. Within 4 weeks prior to the first dose, cardiac ultrasound must demonstrate: left ventricular ejection fraction (LVEF)\\> 50%;\n9. Pregnancy test results must be negative in patients of childbearing age, with voluntary use of effective and reliable contraceptive measures during the study;\n10. Participants must voluntarily enroll in the study, sign an informed consent form, demonstrate good compliance, and agree to participate in follow-up visits.\n\nExclusion Criteria:\n\n1. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer (e.g., germ cell tumors), or ovarian tumors with low malignant potential (e.g., borderline tumors) of non-epithelial origin;\n2. Previous receipt of antitumor therapy, including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy (Note: lymph node dissection or biopsy performed for clinical staging purposes using tissue obtained via puncture biopsy or laparoscopic exploration is permitted);\n3. History of other malignancies within the past 5 years, excluding cured localized tumors (e.g., basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ);\n4. Participation in other drug clinical trials and use of investigational drugs within 4 weeks prior to enrollment;\n5. Administration of live attenuated vaccines within 4 weeks before initial dosing or planned during the study period;\n6. Known history of allergy to any component of this regimen;\n7. Subjects with active infectious diseases;\n8. Subjects with any severe and\u002For uncontrolled diseases;\n9. Active autoimmune diseases requiring systemic treatment within 2 years prior to study initiation, or autoimmune diseases at risk of recurrence; exceptions include: non-systemically treatable dermatoses (e.g., vitiligo, alopecia, psoriasis, or eczema); hypothyroidism due to autoimmune thyroiditis requiring only stable hormone replacement therapy; well-controlled type 1 diabetes mellitus; and conditions deemed by investigators unlikely to recur without external triggers;\n10. Pregnant or breastfeeding women, or women of childbearing potential with positive baseline pregnancy test results.\n11. According to the investigator's assessment, the patient has a severe comorbid condition that poses significant risks to safety or impedes participation in the study, including but not limited to: severe hypertension uncontrolled by medication (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg), myocardial ischemia or myocardial infarction, severe arrhythmias, congestive heart failure grade ≥2, severe pulmonary dysfunction\u002Fdisease, severe diabetes mellitus, or active infections;\n12. A documented history of neurological or psychiatric disorders, including epilepsy or dementia;\n13. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n14. Known history of interstitial lung disease or non-infectious pneumonia;\n15. Diagnosis of immunodeficiency or ongoing systemic glucocorticoid therapy or any other form of immunosuppressive treatment;\n16. Presence of any condition increasing bleeding risk, such as severe hemorrhoids, acute gastritis, or gastric and duodenal ulcers;\n17. History of dysphagia or any gastrointestinal disorder affecting drug absorption;\n18. Any other circumstances deemed inappropriate for study participation by the investigator.",{"count":50,"type":21},35,[24],"The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs. Tyrosine kinase inhibitors (TKIs) can induce immune microenvironment remodeling and exhibit synergistic effects with immune checkpoint inhibitors. To further evaluate the efficacy and safety of epalolide combined with torvolumab plus sunitinib and olaparib as neoadjuvant therapy in HRD-positive untreated patients with advanced ovarian cancer, a prospective, multicenter, single-arm exploratory study is proposed. This study will enroll 35 untreated HRD-positive advanced ovarian cancer patients who will receive neoadjuvant treatment with epalolide plus torvolumab combined with sunitinib and olaparib. Patients achieving CR\u002FPR\u002FSD after neoadjuvant therapy will undergo intermediate tumor cytoreductive surgery, followed by 6 cycles of adjuvant chemotherapy and 1 year of maintenance therapy with the etoricoxib-drug combination antibody regimen. The primary endpoint is R0 resection rate, aiming to provide valuable insights into neoadjuvant treatment strategies for advanced ovarian cancer patients.",[54],"Ovary Cancer","2026-06-19",{"date":57,"type":34},"2026-06-25",{"date":59,"type":34},"2026-06-01",{"date":61,"type":21},"2027-12-31",{"name":40,"class":41},""]